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Pain is a major health problem that significantly affects the qual-
ity of life of patients. It has a significant impact on both the
sufferers and the broader community, imparting high health
costs, and economic loss to society. The consensus among clin-
icians and researchers worldwide is that current strategies for the
treatment of pain are inadequate. These inadequacies are even
greater when chronic pain, which often accompanies chronic ill-
nesses such as arthritis or nerve injury, is involved. Despite major
advances in treatment strategies over the last two decades, pain
management still remains a major challenge in arthritis; and
even with treatment with current therapies, many patients still
experience moderate-to-severe pain (Stein and Baerwald, 2013).
Patients with rheumatoid arthritis report pain management as
their highest priority (Whittle et al., 2013), and osteoarthritis is
the leading cause of pain and physical disability in the elderly
(Stein and Baerwald, 2013). The burden of disease, especially with
osteoarthritis, is growing in relation to the aging population and
the increasing levels of obesity in the world population. Similar
concerns are growing for other types of pain.
Current analgesics for persistent pain are relatively ineffective,
are associated with significant adverse effects or abuse liabil-
ity, and do not reduce pain in all treated individuals (Woolf,
2010). Opioids (e.g., morphine, codeine, oxycodone) are cur-
rently one of the most potent groups of analgesics used clinically
(Iwaszkiewicz et al., 2013), with prescriptions increasing by 50%
over the past 10 years for chronic, non-cancer pain (Waterman,
2013). However there is clear evidence that as opioid prescription
rate rises, there is a corresponding increase in opioid overdose
deaths, misuse and addiction, with these adverse effects attributed
to their agonist effects on central opioid receptors—causing
dependence, tolerance, sedation, and respiratory depression (Hua
and Cabot, 2010; Waterman, 2013). Non-steroidal and steroidal
anti-inflammatory drugs have serious side effects such as gastric
erosions, ulcer formation, bleeding, hypersensitivity reactions,
cardiovascular toxicity, renal toxicity, and hepatotoxicity (Warner
and Mitchell, 2008; Stein et al., 2009). In addition, they are
also not peripherally selective thereby causing a range of cen-
tral adverse effects (Stein et al., 2009). Over the past 20 years,
most analgesic development activity have been limited to refor-
mulation of opioids, production of new cyclooxygenase (COX)
inhibitors, amine reuptake inhibitors and anticonvulsants, and
introduction of topical local anesthetics—all of these act on well-
established targets (Woolf, 2010). Therefore, there is an obvious
clinical need to introduce more effective and safe analgesics,
suitable for chronic administration.
The problem of clinical pain management is complex and far-
reaching, as it encompasses many different types of pain, such
as arthritic, musculoskeletal, neuropathic, and visceral pain. Our
increasing understanding of the neurobiology of pain further sup-
ports that a “one size fits all” policy is not appropriate for the
way we treat pain across different pathological pain conditions as
well as for individuals with the same underlying condition. Pain is
commonly amanifestation of a range of multiple, sometimes irre-
versible, abnormalities in the functioning of the nervous system.
In many cases the problem is the persistent amplification of sen-
sory signals and generation of spontaneous activity in the nervous
system, which occurs in conditions such as fibromyalgia, neuro-
pathic pain, irritable bowel syndrome, and headaches (Woolf and
Salter, 2000; Latremoliere and Woolf, 2009). The complexity and
heterogeneity of pain should be appreciated. Complex interplay
of processes operating at multiple peripheral and central sites are
involved in initiating or sustaining pain, with each mechanism
involving many unique or similar targets (Woolf, 2010).
The driving force for the successful translational development
of novel analgesics requires the collaboration of experts in the
field of basic pain science, pharmaceutics and clinicians special-
izing in pain management. Drug delivery and targeting is now
recognized as the key to effective development of many novel and
existing therapeutics to enable optimal therapeutic use of such
molecules, as many drugs are severely compromised by signifi-
cant obstacles to delivery in vivo and by toxic adverse effects (Hua
and Wu, 2013). Drug delivery systems have been used in pain
therapies to improve toxicity or side effect profiles by targeted
delivery to specific sites in the body, increase drug bioavailabil-
ity, and providing prolonged drug release (Hua and Cabot, 2013;
Hua and Wu, 2013). There is also a need for detailed pheno-
typing of animal models of pain and evaluation of whether the
models are appropriate surrogates for human pain syndromes.
In cases where there is no good rodent model of the disease,
it may be better to model pain mechanisms, such as peripheral
sensitization or ectopic excitability in nociceptors using electro-
physiology (Woolf, 2010). It may be very likely that a single
pain-relieving magic bullet simply does not exist, and instead our
focus may need to turn to multiple targeted treatments and/or
synergistic therapies that are aimed at the specific mechanisms
responsible.
This Research Topic focuses on articles that discuss the mech-
anisms of various types of pain as well as identifying poten-
tial novel targets and new technologies for the development of
innovative therapeutic strategies for the treatment of pain.
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